Dr. Eddrice McMullan praises Accuro for increasing first-attempt success rates and reducing needle passes and placement times, especially in patients with high BMI or scoliosis. “It’s genius,” she says, emphasizing its effectiveness when traditional methods fall short.
Recent Posts
- FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA’s Accuro XV platform
- RIVANNA Crosses 100-patent Threshold: Estate Protects Shared Platform Spanning Multiple FDA-cleared Product Lines
- RIVANNA Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance
- The Inflection Point for Neuraxial Guidance
- Using AI to Strengthen Clinical Confidence: RIVANNA’s Will Mauldin on the Outcomes Rocket Podcast
